Loading...
Loading...
Browse all stories on DeepNewz
VisitGalderma Gains FDA Approval for Nemluvio® to Treat Prurigo Nodularis
Aug 13, 2024, 05:09 AM
Galderma, a Swiss pharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) for its drug Nemluvio® (nemolizumab). This medication is intended for adult patients suffering from Prurigo Nodularis, a chronic skin condition characterized by itchy nodules. The FDA approval marks a significant advancement for Galderma in the U.S. market, providing a new treatment option for patients with this challenging dermatological condition.
View original story
Markets
No • 50%
Yes • 50%
FDA announcements or Galderma's press releases
Yes • 50%
No • 50%
Official announcements from Galderma or major pharmaceutical distribution channels
No • 50%
Yes • 50%
Galderma's financial reports or credible market analysis reports
Less than 10% • 25%
More than 50% • 25%
25% to 50% • 25%
10% to 25% • 25%
Market research reports from credible sources like IMS Health or IQVIA
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
Market research reports and industry analysis
South • 25%
West • 25%
Northeast • 25%
Midwest • 25%
Sales data from Galderma or market research reports